Using Keytruda for Mesothelioma May Become a Reality
The U.S. Food and Drug Administration recently upgraded its approval of pembrolizumab (Keytruda) for metastatic non-small cell lung cancer, inching it closer to becoming an accepted treatment option for pleural mesothelioma. Pembrolizumab, produced by pharmaceutical giant Merck & Co., also is marketed as Keytruda. The FDA’s announcement last week converted its previous “accelerated” approval in…
The post Using Keytruda for Mesothelioma May Become a Reality appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.